BOCOM International maintains a 'Buy' rating for SIMCERE PHARMA due to its expected strong revenue and profit growth in the coming years, driven by new product launches and an expanding pipeline in innovative areas. The firm anticipates significant growth in both revenue and adjusted net profit, projecting them to reach approximately RMB10 billion and RMB1.6 billion by 2026, and over RMB20 billion and RMB3 billion by 2030.
